JP5800834B2 - ハリコンドリンb類似体の合成において有用なフロ[3,2−b]ピラン誘導体 - Google Patents

ハリコンドリンb類似体の合成において有用なフロ[3,2−b]ピラン誘導体 Download PDF

Info

Publication number
JP5800834B2
JP5800834B2 JP2012551271A JP2012551271A JP5800834B2 JP 5800834 B2 JP5800834 B2 JP 5800834B2 JP 2012551271 A JP2012551271 A JP 2012551271A JP 2012551271 A JP2012551271 A JP 2012551271A JP 5800834 B2 JP5800834 B2 JP 5800834B2
Authority
JP
Japan
Prior art keywords
sulfonate
heteroaryl
alkyl
aryl
hydroxyl protecting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012551271A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013518116A (ja
JP2013518116A5 (enExample
Inventor
遠藤,篤史
チェース,チャールズ,イー.
ファン,フランシィス,ジー.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of JP2013518116A publication Critical patent/JP2013518116A/ja
Publication of JP2013518116A5 publication Critical patent/JP2013518116A5/ja
Application granted granted Critical
Publication of JP5800834B2 publication Critical patent/JP5800834B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/12Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2012551271A 2010-01-26 2011-01-26 ハリコンドリンb類似体の合成において有用なフロ[3,2−b]ピラン誘導体 Active JP5800834B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29833710P 2010-01-26 2010-01-26
US61/298,337 2010-01-26
PCT/US2011/022611 WO2011094339A1 (en) 2010-01-26 2011-01-26 Furo [3, 2 -b] pyrane derivatives useful in the synthesis of halichondrin b analogs

Publications (3)

Publication Number Publication Date
JP2013518116A JP2013518116A (ja) 2013-05-20
JP2013518116A5 JP2013518116A5 (enExample) 2014-03-13
JP5800834B2 true JP5800834B2 (ja) 2015-10-28

Family

ID=43726543

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012551271A Active JP5800834B2 (ja) 2010-01-26 2011-01-26 ハリコンドリンb類似体の合成において有用なフロ[3,2−b]ピラン誘導体

Country Status (11)

Country Link
US (6) US8203010B2 (enExample)
EP (1) EP2528914B1 (enExample)
JP (1) JP5800834B2 (enExample)
CN (1) CN102803254B (enExample)
BR (1) BR112012018232B8 (enExample)
CA (1) CA2787919C (enExample)
IL (1) IL220913A (enExample)
MX (1) MX2012008510A (enExample)
RU (1) RU2579511C2 (enExample)
SG (2) SG182612A1 (enExample)
WO (1) WO2011094339A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2755266C (en) * 1998-06-17 2014-08-12 Eisai R&D Management Co., Ltd. Intermediates for preparing macrocyclic analogs
AU2005250487B2 (en) 2004-06-03 2012-03-29 Eisai R&D Management Co., Ltd Intermediates for the preparation of analogs of halichondrin B
EP2200992B1 (en) 2007-10-03 2014-02-26 Eisai R&D Management Co., Ltd. Intermediates and methods for the synthesis of halichondrin b analogs
JP6001857B2 (ja) * 2008-04-04 2016-10-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 ハリコンドリンb類似体
AU2010232347A1 (en) 2009-03-30 2011-09-29 Eisai R&D Management Co., Ltd. Liposome composition
BR112012018232B8 (pt) 2010-01-26 2023-01-10 Eisai R&D Man Co Ltd Compostos derivados de furo [3,2-b] pirano úteis na síntese de análogos de halicondrina b e métodos de sintetização de er-80402 e de eribulina
CN110097416B (zh) 2011-09-18 2022-05-10 踏途音乐公司 具有卡拉ok和照相亭功能的数字点播设备及相关方法
CA2892780A1 (en) 2012-12-04 2014-06-12 Eisai R&D Management Co., Ltd. Use of eribulin in the treatment of breast cancer
AU2014299699B2 (en) 2013-06-26 2019-10-10 Eisai R&D Management Co., Ltd. Use of eribulin and lenvatinib as combination therapy for treatment of cancer
WO2015000070A1 (en) 2013-07-03 2015-01-08 Alphora Research Inc. Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein including intermediates containing -so2-(p-tolyl) groups
CN103483352A (zh) * 2013-10-18 2014-01-01 李友香 抗肿瘤的药用原料药
RU2710545C2 (ru) 2013-11-04 2019-12-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Реакции макроциклизации и промежуточные соединения и другие фрагменты, пригодные в получении аналогов халихондрина b
MX384292B (es) 2013-12-06 2025-03-14 Eisai R&D Man Co Ltd Metodos utiles en la sintesis de analogos de halicondrina b.
EP3148526B1 (en) 2014-05-28 2021-01-06 Eisai R&D Management Co., Ltd. Use of eribulin in the treatment of cancer
JP2017520586A (ja) 2014-06-30 2017-07-27 プレジデント アンド フェローズ オブ ハーバード カレッジ ハリコンドリン類似体の合成およびその使用
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
KR20170122810A (ko) 2015-03-04 2017-11-06 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 에리불린의 조합
US10344038B2 (en) 2015-04-30 2019-07-09 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
RU2739034C2 (ru) * 2015-05-07 2020-12-21 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Реакции макроциклизации и промежуточное соединение и другие фрагменты, полезные в синтезе макролидов галихондринов
KR20180107243A (ko) 2016-02-12 2018-10-01 에자이 알앤드디 매니지먼트 가부시키가이샤 에리불린의 합성에서의 중간체 및 관련된 합성 방법
RS62108B1 (sr) 2016-03-02 2021-08-31 Eisai R&D Man Co Ltd Antitelo-lek konjugati na bazi eribulina i postupci primene
EP3449921B1 (en) 2016-04-28 2023-05-31 Eisai R&D Management Co., Ltd. Eribulin for inhibiting tumor growth
US11136335B2 (en) 2016-06-30 2021-10-05 Eisai R&D Management Co., Ltd. Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof
MX2019003994A (es) 2016-10-14 2019-09-19 Merck Sharp & Dohme Combinacion de un antagonista de proteina de muerte programada-1 (pd-1) y eribulina para el tratamiento de cancer urotelial.
JP6978758B2 (ja) 2016-11-11 2021-12-08 プレジデント アンド フェローズ オブ ハーバード カレッジ パラジウム媒介ケトール化
CN108658956B (zh) * 2017-03-28 2021-02-02 上海时莱生物技术有限公司 艾日布林中间体及其制备方法
US9938288B1 (en) 2017-04-05 2018-04-10 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
TWI863657B (zh) 2017-04-05 2024-11-21 哈佛大學校長及研究員協會 巨環化合物及其用途
CN108948064B (zh) * 2017-05-17 2021-02-02 上海时莱生物技术有限公司 一种艾日布林中间体及其制备方法
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
CN118515685A (zh) 2017-07-06 2024-08-20 哈佛大学的校长及成员们 软海绵素的合成
US20190046513A1 (en) 2017-08-10 2019-02-14 Huya Bioscience International, Llc Combination therapies of hdac inhibitors and tubulin inhibitors
EP4403560A3 (en) 2017-11-15 2024-10-23 President And Fellows Of Harvard College Macrocyclic compounds and uses thereof
US11419856B2 (en) 2017-11-20 2022-08-23 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
EP3737673B1 (en) 2018-01-03 2024-03-06 Eisai R&D Management Co., Ltd. Process for preparing halichondrin macrolides and analogs thereof by a prins reaction, and intermediates of this process
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU652180A1 (ru) * 1975-12-16 1979-03-15 Краснодарский политехнический институт 1(Фурил-2,)-2-(2-,, формилфурил-5,, ) этилен или его метильное производное как промежуточный продукт дл синтеза фуран-2,5-дикарбоновой кислоты и способ его получени
US5338865A (en) * 1992-03-12 1994-08-16 President And Fellows Of Harvard College Synthesis of halichondrin B and norhalichondrin B
US5436238A (en) * 1992-03-12 1995-07-25 President And Fellows Of Harvard College Halichondrins and related compounds
GB9206244D0 (en) 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
TW255880B (enExample) 1992-09-09 1995-09-01 Hoechst Ag
US6194586B1 (en) 1996-09-06 2001-02-27 Eli Lilly And Company Selective sulphonation of the primary alcohol of a diol containing both primary and secondary alcohols
US6653341B1 (en) * 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
US8097648B2 (en) 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
CA2755266C (en) * 1998-06-17 2014-08-12 Eisai R&D Management Co., Ltd. Intermediates for preparing macrocyclic analogs
CN109180615A (zh) * 2004-06-03 2019-01-11 卫材R&D管理有限公司 用于制备软海绵素b的类似物的中间体
AU2005250487B2 (en) 2004-06-03 2012-03-29 Eisai R&D Management Co., Ltd Intermediates for the preparation of analogs of halichondrin B
US20060045846A1 (en) 2004-08-30 2006-03-02 Horstmann Thomas E Reagents and methods for labeling terminal olefins
WO2006076100A2 (en) 2004-12-09 2006-07-20 Eisai Co. Ltd. Tubulin isotype screening in cancer therapy using halichondrin b analogs
WO2008010776A1 (en) 2006-07-21 2008-01-24 Agency For Science, Technology And Research Aigialomycin d and derivatives thereof and their use in treating cancer or malaria or a microbial infection
EP2200992B1 (en) 2007-10-03 2014-02-26 Eisai R&D Management Co., Ltd. Intermediates and methods for the synthesis of halichondrin b analogs
CA2705383A1 (en) 2007-11-16 2009-05-22 Eisai R&D Management Co., Ltd. Novel intermediate for halichondrin b analog synthesis and novel desulfonylation reaction used for the intermediate
JP6001857B2 (ja) 2008-04-04 2016-10-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 ハリコンドリンb類似体
BR112012018232B8 (pt) 2010-01-26 2023-01-10 Eisai R&D Man Co Ltd Compostos derivados de furo [3,2-b] pirano úteis na síntese de análogos de halicondrina b e métodos de sintetização de er-80402 e de eribulina
WO2012147900A1 (en) 2011-04-28 2012-11-01 Eisai R&D Management Co., Ltd. Microreactor process for halichondrin b analog synthesis
WO2013078559A1 (en) 2011-11-30 2013-06-06 Alphora Research Inc. Process for preparation of (3r)-2,4-di-leaving group-3-methylbut-1-ene
WO2013142999A1 (en) 2012-03-30 2013-10-03 Alphora Research Inc. Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein
WO2015000070A1 (en) 2013-07-03 2015-01-08 Alphora Research Inc. Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein including intermediates containing -so2-(p-tolyl) groups
RU2710545C2 (ru) 2013-11-04 2019-12-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Реакции макроциклизации и промежуточные соединения и другие фрагменты, пригодные в получении аналогов халихондрина b
MX384292B (es) 2013-12-06 2025-03-14 Eisai R&D Man Co Ltd Metodos utiles en la sintesis de analogos de halicondrina b.
RU2739034C2 (ru) 2015-05-07 2020-12-21 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Реакции макроциклизации и промежуточное соединение и другие фрагменты, полезные в синтезе макролидов галихондринов
KR20180107243A (ko) 2016-02-12 2018-10-01 에자이 알앤드디 매니지먼트 가부시키가이샤 에리불린의 합성에서의 중간체 및 관련된 합성 방법
US11136335B2 (en) 2016-06-30 2021-10-05 Eisai R&D Management Co., Ltd. Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof

Also Published As

Publication number Publication date
RU2579511C2 (ru) 2016-04-10
EP2528914B1 (en) 2014-06-11
SG10201500552PA (en) 2015-03-30
WO2011094339A1 (en) 2011-08-04
US9382262B2 (en) 2016-07-05
MX2012008510A (es) 2012-11-21
US9856276B2 (en) 2018-01-02
US8350067B2 (en) 2013-01-08
US20130123519A1 (en) 2013-05-16
US8927597B2 (en) 2015-01-06
JP2013518116A (ja) 2013-05-20
BR112012018232B8 (pt) 2023-01-10
CN102803254A (zh) 2012-11-28
US20150175620A1 (en) 2015-06-25
CN102803254B (zh) 2016-09-14
EP2528914A1 (en) 2012-12-05
BR112012018232B1 (pt) 2022-11-29
BR112012018232A2 (pt) 2016-02-23
CA2787919A1 (en) 2011-08-04
US20160376294A1 (en) 2016-12-29
IL220913A (en) 2016-11-30
US20120289718A1 (en) 2012-11-15
SG182612A1 (en) 2012-08-30
US20110184190A1 (en) 2011-07-28
RU2012136468A (ru) 2014-03-10
CA2787919C (en) 2018-07-31
US10494388B2 (en) 2019-12-03
US20180162885A1 (en) 2018-06-14
US8203010B2 (en) 2012-06-19

Similar Documents

Publication Publication Date Title
JP5800834B2 (ja) ハリコンドリンb類似体の合成において有用なフロ[3,2−b]ピラン誘導体
CA2935786C (en) Intermediates for the preparation of analogs of halichondrin b
KR101210018B1 (ko) 약물로서 유용한 거대고리 화합물
JPS6323878A (ja) 7−アシルオキシ−6−アミノアシルオキシポリオキシラブダンおよびその製法
CA2822994C (en) Intermediates for the preparation of analogs of halichondrin b
WO2005023792A2 (en) Macrocyclic compounds useful as pharmaceuticals
CA2395652C (fr) Nouveaux derives de benzo[b]pyrano[3,2-h]acridin-7-one, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2009513710A (ja) ジアゾンアミドa類似体
JPH0625214A (ja) 新規7−アミノラブダン類、その製造方法および製剤としてのその用途
FR3022907A1 (fr) Derives d'osw-1 et leur utilisation en tant que medicament

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150223

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150728

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150825

R150 Certificate of patent or registration of utility model

Ref document number: 5800834

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250